• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2021 Fiscal Year Final Research Report

Treatment strategy of amyotrophic lateral sclerosis focusing on controlling spinal blood flow and metabolism

Research Project

  • PDF
Project/Area Number 19K07822
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 51030:Pathophysiologic neuroscience-related
Research InstitutionOsaka University

Principal Investigator

TADA Satoru  大阪大学, 医学系研究科, 招へい教員 (70626530)

Co-Investigator(Kenkyū-buntansha) 奥野 龍禎  大阪大学, 医学系研究科, 准教授 (00464248)
清水 幹人  大阪大学, 医学部附属病院, 医員 (30817507)
Project Period (FY) 2019-04-01 – 2022-03-31
Keywords運動神経変性 / 運動ニューロン疾患 / 低酸素 / 低灌流 / 血管拡張
Outline of Final Research Achievements

To further confirm the mechanism of response to the novel vasodilator (ONO1301) identified in the previous study, HSP70, one of the downstream molecules of HIF1a, a hypoxia-inducing molecule, was confirmed by immunostaining. Specifically, we compared the expression of HSP70 in the spinal cord of ALS model mice treated with ONO1301 and the target treatment group mice, and found that HSP70 signal was reduced in the ONO1301 group, reflecting the improvement in blood flow induced by ONO1301. Based on these findings, the investigators sought to determine whether oral vasodilator X, which is already in clinical use as a vasodilator, could exert a similar neuroprotective effect in ALS model mice.

Free Research Field

神経内科学

Academic Significance and Societal Importance of the Research Achievements

筋萎縮性側索硬化症(amyotrophic lateral sclerosis, ALS)は、疾患進行を抑制する根治療法の存在しない神経変性疾患である。人工呼吸器がなければ、患者は発症後3-5年で呼吸不全のため死去するため、その治療法の開発が喫緊の課題である。現在保険適応を受けている治療は2種類存在するが、いずれも患者の生存期間を延長する効果はない。我々の知見により、これらの治療法に加えて血管拡張療法が臨床的に有用である可能性が示唆され、患者寿命を進展できる可能性を見出したことが、本研究の最大の意義である。

URL: 

Published: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi